Abivax SA banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
France FR
Employees
80
IPO date
Jun 26, 2015

Abivax is a biotechnology company that develops drug candidates for inflammatory and immune-driven diseases. Its main work is research and clinical testing, especially for conditions like ulcerative colitis, where it is trying to turn its lead molecule into a prescription medicine. It is not a broad drug seller; it is a drug developer that owns and advances its own clinical programs.

Because it does not yet have a large marketed drug portfolio, Abivax makes money mainly through financing its research and, if a program succeeds, through future drug sales or licensing deals. Its eventual customers would be patients, doctors, hospitals, and pharmacies that use the medicines it develops. In the value chain, it sits at the high-risk discovery and clinical-development stage, before large-scale commercial manufacturing and distribution.

What makes Abivax different is that its business depends on one or a few scientific programs rather than a wide product lineup. That means the company’s value comes from its patents, trial data, and regulatory progress, not from selling many different products today. For investors, it is best understood as a focused biotech research company with the goal of turning a specific drug candidate into an approved treatment.

Abivax SA Investor Relations

Address
7-11 Boulevard Haussmann
Paris, Ile-De-France
France

Business Segments

Drug development

Abivax develops and tests medicines that act on the immune system, with a focus on inflammatory and chronic diseases. Its work centers on advancing drug candidates through laboratory research and clinical trials until they can be approved and sold.

Customers

Patients with inflammatory or chronic diseases are the end users, while doctors, hospitals, and drug regulators are the groups that decide whether the medicines can be used.

Revenue Model

The company can earn money through collaboration and licensing deals during development, and later through sales of approved medicines or royalty income if partners commercialize them.

Management

Mr. Marc M. P. de Garidel M.B.A.

CEO & Director

Biography unavailable

Dr. Philippe Pouletty M.D., Ph.D.

Founder & Director

Biography unavailable

Mr. Didier Blondel

EVP, CFO & Board Secretary

Biography unavailable

Mr. Didier Scherrer Ph.D.

Chief Scientific Officer

Biography unavailable

Mr. Patrick Malloy

Senior Vice President of Investor Relations

Biography unavailable

Ms. Ida Hatoum

Chief People & Compliance Officer

Biography unavailable

Mr. Pierre Courteille M.B.A.

Chief Business Officer

Biography unavailable

Mr. Jerome Denis Ph.D.

Executive Vice President of Process Development & Manufacturing

Biography unavailable

Ms. Ana Sharma M.P.H.

VP & Global Head of Quality

Biography unavailable

Hema Keshava

Senior Vice President of Finance

Biography unavailable

1 / 10